Abgenom was formed in 2005 as a privately
held biotech R & D company with a mission to improve
human health and society by understanding and
applying the power of biology to develop
breakthrough research technologies and products to
improve the human condition, specifically focusing
on the discovery, development and commercialization
of novel, patent protected diagnostic products with
high clinical value.
Abgenom makes differences by developing
innovative products to detect cardiovascular diseases
and infectious diseases / zoonoses. Through its immuno-
and proteomics research efforts, Abgenom is
also identifying and validating novel diagnostic
markers, and is seeking to develop diagnostic products
based on these markers.
Abgenom owns or has exclusively licensed
patents or patent applications covering different
technology platforms and their applications, i.e.
nano-colloidal gold technologies for developing rapid
test devices; Real-time qPCR for rapid detecting various
pathogens simultaneously; and integrated diagnostic
chips to simultaneously detect various pathogens, virus
and antibodies. As regard to applications, our patents
cover different groups of diseases such as
cardiovascular disease, STD, virus hepatitis, rabies
virus, and multiple HIV antibodies.
Abgenom’s products also serve the needs of
some markets outside of life science research, which we
refer to as “applied markets,” such as the fields of
human good prenatal and postnatal care (early pregnancy,
ovulation and sterility testing); biosecurity, which
refers to products needed in response to the threat of
biological terrorism and other malicious, accidental,
and natural biological dangers; and quality and safety
testing, for example in food, feed and the environment.
Investors/parties interested in equity or acquisition are
welcome to contact us directly.